Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monometl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monometl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
Zilovertamab vedotin (VLS-101; 0-100 μg/mL) induces cytotoxicity in ROR1+ primary MCL cells in a dose-dependent manner[1].Zilovertamab vedotin (24h; ibrutinib-sensitive (JeKo-1) and resistant (JeKo BTK KD_2) cell lines) induces cell apoptosis and cell cycle arrest at G2/M[1].
Zilovertamab vedotin (VLS-101; 2.5 mg/kg; i.v.; weekly, for 3 weeks) targets ROR1-expressing PDX models with dual resistance to ibrutinib and CAR T. A PDX model. Zilovertamab vedotin inhibits tumor growth[1].
References:
[1]. Jiang VC, et, al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021 Aug 28;14(1):132.